The anti-PD1 drug nivolumab has been the first ICI drug to obtain approval by the FDA and European Commission for the treatment of RCC, and showed a significant OS benefit in patients with RCC that progressed following antiangiogenic therapy compared with everolimus (mTOR inhibitor) (26). The gene discussed is MTOR; the disease is renal cell adenocarcinoma.